Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season If approved by the European ...
Merck (NYSE:MRK) announced on Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed Enflonsia, a prophylactic antibody therapy developed by the company to ...
About ENFLONSIA™ (clesrovimab-cfor) in the U.S. ENFLONSIA is Merck’s FDA-approved, extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results